Q-omics provides the consensus-scored MDM4 profile across patient tissues and cancer cell-line models. MDM4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MDM4 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, MDM4 RNA expression shows 21,635 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where MDM4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MDM4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MDM4 survival associations across molecular data types. MDM4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MDM4 RNA expression–survival associations across cancer types. High MDM4 expression shows unfavorable associations in ACC, KIRC, LGG and KICH, but favorable associations in BLCA and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MDM4 RNA expression.
This table summarizes MDM4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MDM4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MDM4 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, KIRC, COAD and CHOL. The HNSC box plot shows higher MDM4 RNA expression in tumor versus normal tissue (log2 FC = +0.369, t-test p = .001).
This table shows molecular features associated with MDM4 in patient tissues and cancer cell lines. In patient samples, MDM4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MDM4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
